That blueprint offers a series of clear policy prescriptions that will help the Trump administration make its healthcare vision a reality for Americans. Importantly, it does so without introducing counterproductive price controls that would only end up threatening future innovation, hurting the U.S. economy and depriving patients of critical lifesaving drugs and care.

Tweet

Just six months in, the Trump administration has wasted no time dismantling many failed Biden administration policies.  From securing the nation’s borders to reducing inflation to improving energy security to supporting Israel, President Trump is delivering on his promises to the American people.  

For American consumers, a significant pillar of President Trump’s agenda is his commitment to domestic healthcare reform that delivers lower costs, greater access to lifesaving medicines and higher quality care for patients.  That also means encouraging more domestic manufacturing, and finally holding European and other developed nations accountable after decades of free riding on American investment, research and development, and innovation.  

In the effort to achieve those critical healthcare reform goals, this month witnessed the launch of the “Most Favored Patient” initiative, a bold new policy blueprint led by prominent free-market and pro-intellectual property (IP) voices Steve Forbes, Stephen Moore, Phil Kerpen and Thomas Philipson from Unleash Prosperity Now.  That blueprint offers a series of clear policy prescriptions that will help the Trump administration make its healthcare vision a reality for Americans.  Importantly, it does so without introducing counterproductive price controls that would only end up threatening future innovation, hurting the U.S. economy and depriving patients of critical lifesaving drugs and care.  

For proper context, it’s important to recall the dangerous ways in which the Biden administration inexplicably acted to undermine U.S. drug preeminence and innovation, and in turn threatened consumer access to existing and future lifesaving medicines.  

Things got off to an inauspicious start just weeks into Biden’s presidency, when he began flirting with the idea of unilaterally surrendering U.S. drug companies’ patents under pressure from domestic and international voices.  

Things only got worse from there.  

The Biden administration proceeded to undertake a litany of destructive pharmaceutical policies, including price controls, further patent violations and higher taxes.  That included a proposal to “march in” and seize drug patents under the Bayh-Dole Act of 1980, which The Economist labeled the most important legislation of the past four decades, and which was enacted to promote patents, not undermine them.  

Collectively, for four years the Biden administration’s zeal for aggressive government intervention from weakening patents to imposing broad price controls worked to undercut the engines that power medical progress in America.  

Enter the second Trump administration.  As with so many other issues, it possesses an ideal opportunity to correct course on the Biden administration’s destructive healthcare and prescription drug policies.  

This month’s debut of the Most Favored Patient initiative and its policy agenda provides a roadmap for the Trump administration to make good on its vision.  

To achieve that meaningful healthcare and drug policy reform, Most Favored Patient encourages (1) direct-to-consumer pharmaceutical purchasing, thereby eliminating costly intermediaries;  (2)  ensuring that foreign nations pay a more fair share for U.S.-developed drugs, thereby discouraging the persistent free-rider problem referenced above;  (3)  increasing incentives for domestic research and development, manufacturing and workforce growth, thereby deepening domestic employment and national security;  and (4)  reforming insurer and pharmacy benefit manager (PBM) operations, thereby requiring that rebates and discounts be passed directly to consumers and boosting overall price transparency.  

As a central part of that effort, Most Favored Patient released a new public opinion survey of voters in key Congressional battleground districts.  As the poll notes, voters “overwhelmingly support market-based reforms to make healthcare and prescription drugs more affordable for Americans, providing President Trump an opportunity to lower U.S. drug prices through direct-to-consumer sales; make foreign countries pay their fair share for American innovation; rein in middlemen; and bring transparency and efficiency to America’s healthcare system.”  

The easy-to-read survey is worth viewing for the way it shows upwards of 80% support from Democrats, independents and Republicans alike for many of those propositions, in line with Trump’s successful “80/20” strategy on other policy issues.  

Accordingly, it isn’t just good policy, it’s politically popular.  

The Most Favored Patient reform initiative can ensure that Americans continue to benefit from the world’s leading source of medical breakthroughs while Europe and other nations finally pay their fair share. It delivers on the Trump administration’s vision of a healthcare and pharmaceutical sector that promises higher quality and lower prices for Americans, as well as a welcome change from the destructive Biden years.  

That’s good news for consumers, both here and abroad.